Terms ending in 2032
Every in-force patent on Lonza Ltd.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,214,560 | Branched Linker for Protein Drug Conjugates In force · High confidence | Lonza Guangzhou Pharmaceutical Ltd. | In force | High confidence | |
| US 10,294,270 | Branched Linker for Protein Drug Conjugates In force · High confidence | Lonza Guangzhou Pharmaceutical Ltd. | In force | High confidence | |
| US 10,130,602 | Use of L-Carnitine, Salts and Derivatives Thereof for Reducing or Preventing Fatigue and Improving Cognitive Function In force · High confidence | Capsugel Switzerland AG | In force | High confidence | |
| US 8,779,188 | Process for the Production of L-Carnitine Tartrate In force · High confidence | Capsugel Switzerland AG | In force | High confidence | |
| US 9,227,905 | Process for the Production of 4-Chloroacetoacetyl Chloride, 4-Chloroacetoacetic Acid Esters, Amides and Imides In force · High confidence | Capsugel Switzerland AG | In force | High confidence | |
| US 9,512,432 | Regulatable Promoter In force · High confidence | Lonza Ltd. | In force | High confidence | |
| US 10,301,634 | Regulatable Promoter In force · Low confidence | Lonza Ltd. | In force | Low confidence | |
| US 11,976,284 | Promoter Variants for Protein Production In force · High confidence | Lonza Ltd. | In force | High confidence | |
| US 9,415,346 | Process for the Recovery of Betaines from Electrodialysis Waste Streams In force · High confidence | Capsugel Switzerland AG | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Lonza Ltd..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.